Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Introduction. The article considers approaches to the management of patients with inflammatory diseases of the middle ear at the outpatient and hospital stages.Aim. To substantiate the guidelines for endaural treatment of inflammatory ear diseases with Anauran® ear drops from the perspective of the best clinical efficiency.Materials and methods. A total of 53 patients (106 ears) were examined, of which 21 patients were diagnosed with otitis externa diffusa (24 ears), 23 patients (25 ears) with acute catarrhal otitis media and 9 patients (9 ears) with epitympanitis in remission, who underwent type 1 tympanoplasty. The efficacy of Anauran® as part of combination treatment was compared in the following age groups: in patients over 18 years old (mean age 39.2 ± 11.1 years) and in children (mean age 9.8 ± 6.5 years).Results and discussion. Absolute scores determined in assessing ear pain in the group of patients with acute otitis externa diffusa ranged from 3 to 9 scores; in the group with acute catarrhal otitis media – from 3 to 8 scores, in patients after tympanoplasty – from 2 to 8 scores. There was some difference in the assessment of the ear pain severity between children and patients over 18 years of age. The most short-term changes in ear pain occurred in children with acute otitis externa diffusa and acute catarrhal otitis media. As a result, the vast majority of patients showed a clinical effect on Day 7, which consisted in the recovery of the otoscopic status, a decrease in complaints by up to 96.3% in adults and up to 96.1% in children. The use of Anauran® ear drops in the complex management of patients with inflammatory diseases of the middle ear reduces the duration of treatment and eliminates problems with secondary bacterial infections in the postoperative period.Conclusions. The findings support the high efficiency of Anauran® in the combination therapeutic treatment of inflammatory processes of the outer and middle ear.
Introduction. The article considers approaches to the management of patients with inflammatory diseases of the middle ear at the outpatient and hospital stages.Aim. To substantiate the guidelines for endaural treatment of inflammatory ear diseases with Anauran® ear drops from the perspective of the best clinical efficiency.Materials and methods. A total of 53 patients (106 ears) were examined, of which 21 patients were diagnosed with otitis externa diffusa (24 ears), 23 patients (25 ears) with acute catarrhal otitis media and 9 patients (9 ears) with epitympanitis in remission, who underwent type 1 tympanoplasty. The efficacy of Anauran® as part of combination treatment was compared in the following age groups: in patients over 18 years old (mean age 39.2 ± 11.1 years) and in children (mean age 9.8 ± 6.5 years).Results and discussion. Absolute scores determined in assessing ear pain in the group of patients with acute otitis externa diffusa ranged from 3 to 9 scores; in the group with acute catarrhal otitis media – from 3 to 8 scores, in patients after tympanoplasty – from 2 to 8 scores. There was some difference in the assessment of the ear pain severity between children and patients over 18 years of age. The most short-term changes in ear pain occurred in children with acute otitis externa diffusa and acute catarrhal otitis media. As a result, the vast majority of patients showed a clinical effect on Day 7, which consisted in the recovery of the otoscopic status, a decrease in complaints by up to 96.3% in adults and up to 96.1% in children. The use of Anauran® ear drops in the complex management of patients with inflammatory diseases of the middle ear reduces the duration of treatment and eliminates problems with secondary bacterial infections in the postoperative period.Conclusions. The findings support the high efficiency of Anauran® in the combination therapeutic treatment of inflammatory processes of the outer and middle ear.
Introduction. Polyethologicity of otitis externa with inflammation of the auricle, ear canal and outer layer of the eardrum, persistent course and high probability of recurrence necessitates improved treatment.Aim. To evaluate the effectiveness of the use and the impact on the quality of life of combined ear drops with antimicrobial and local anesthetic effects.Materials and methods. A simple randomized controlled clinical trial involved 56 people, including 25 women and 31 men aged 32 to 56 years, suffering from acute diffuse otitis externa. Clinical efficacy, recovery time and impact on quality of life were evaluated in two groups: groups 1 (n = 27), patients receiving ear drops containing choline acetate as local therapy, with group 2 (n = 29) taking a multicomponent drug containing polymyxin B sulfate 1,000,000 IU, neomycin sulfate 0.5 g (375,000 IU) and lidocaine hydrochloride in the form of ear drops. The assessment of otalgia, hearing loss and discharge from the external auditory canal was carried out on the VAS, quality of life scale using the SF-36 general questionnaires.Results and discussion. There was a positive dynamic of clinical manifestations and restoration of quality-of-life indicators in a shorter period (3rd, 5th day) with the disappearance of all the main clinical symptoms (7th day) with good tolerability and absence of side effects in the second group of patients taking the multicomponent drug.Conclusions. The use of ear drops containing a combination of topical antimicrobial drugs with an anesthetic in the complex therapy of otitis externa significantly improved the clinical symptoms and quality of life of patients.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.